DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kahl S, Gancheva S, Straßburger K. et al.
Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial.
Diabetes Care 2020;
43 (02) 298-305
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.